COMPANY SUMMARY BIO Boston 1x1 meeting NOSOPHARM ___________ NAME - - PDF document

COMPANY SUMMARY BIO Boston 1x1 meeting

NOSOPHARM ___________ NAME OF THE CEO Philippe VILLAIN-GUILLOT ADRESS 21 av Georges Pompidou Danica B 69486 Lyon Cedex 03 ________________________ EMAIL p.villainguillot@nosopharm.com www.nosopharm.com MANAGEMENT TEAM CEO: Philippe VILLAIN-GUILLOT CSO: Maxime GUALTIERI TARGETED MARKET ___________ The business model of Nosopharm is to feed the antimicrobial pipeline

• f the Pharma and Biotech

companies with novel first-in-class anti-infective agents developed up to Phase 1 clinical trials. NOSO- 502, the first clinical candidate of the new Odilorhadbin antibiotic class, targets the treatment of multidrug-resistant Enterobacteriaceae infections, including carbapenem-resistant Enterobacteriaceae (CRE), a pathogen categorized as an urgent threat by the CDC (Center for Disease Control & Prevention) PRIVATE COMPANY CREATION DATE March 2009

MISSION

The mission of Nosopharm is to discover and develop novel first-in-class anti- infective agents addressing the treatment of severe and life-threatening multidrug- resistant hospital -acquired infections.

TECHNOLOGY

Nosopharm has designed and developed a proprietary innovative and unique anti- infective drug discovery platform based on an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

COMPETITION

Competitors with first-in-class antibacterials under development: Bugworks, Curza, Forge Therapeutics, Polyphor Competitors with first-in-class antifungals under development: Scynexis, Vical

ALLIANCES/PARTNERSHIPS

European R&D consortium IMI ND4BB ENABLE (http://nd4bb-enable.eu/) University of Illinois at Chicago

UPCOMING CATALYSTS

IND approval for the first-in-class antibiotic NOSO-502 Qualified Infectious Disease Product designation by the FDA for NOSO-502 Phase 1 clinical trials for NOSO-502 Discovery and development of a new class of antibiotics for the treatment of Pseudomonas aeruginosa infection Discovery and development of a new class of antifungals for the treatment of Candida infection, especially the multidrug-resistant Candida glabrata and Candida auris

KEY FIGURES SHAREHOLDERS (percentage)

Funders (Philippe VILLAIN-GUILLOT, Maxime GUALTIERI): 31.7% Venture Capital (Auriga, Kreaxi, Alto Invest): 34.3% Business angels: 34.0%

PIPELINE COMPANY SUMMARY BIO Boston 1x1 meeting

€ m 2016 2017 Sales EBIT

• 0,9
• 1,5

Net Income

• 0.4
• 0,9

Cash Position 0,5 1,8

Target Pathogen Product Candidate Class Discovery Lead to Candidate IND- enabling Phase 1 Enterobacteriaceae NOSO-502 Odilorhabdin

• P. aeruginosa

NOSO-A4 Madelorhabdin Candida spp. NOSO-F2 Candidarhabdin

NOSOPHARM ___________ NAME OF THE CEO Philippe VILLAIN-GUILLOT ADRESS 21 av Georges Pompidou Danica B 69486 Lyon Cedex 03 ________________________ EMAIL p.villainguillot@nosopharm.com www.nosopharm.com MANAGEMENT TEAM CEO: Philippe VILLAIN-GUILLOT CSO: Maxime GUALTIERI TARGETED MARKET ___________ The business model of Nosopharm is to feed the antimicrobial pipeline

• f the Pharma and Biotech

companies with novel first-in-class anti-infective agents developed up to Phase 1 clinical trials. NOSO- 502, the first clinical candidate of the new Odilorhadbin antibiotic class, targets the treatment of multidrug-resistant Enterobacteriaceae infections, including carbapenem-resistant Enterobacteriaceae (CRE), a pathogen categorized as an urgent threat by the CDC (Center for Disease Control & Prevention) PRIVATE COMPANY CREATION DATE March 2009